1. Introduction {#sec1}
===============

End-stage renal disease (ESRD) under regular renal replacement treatment, such as hemodialysis (HD), peritoneal dialysis, and transplantation, is a worldwide public health problem. The global prevalence of ESRD is 280 per million population \[[@B1]\]. According to the most recent United States Renal Data System (USRDS) database, the prevalence of CKD was 15%, and ESRD was 2160.7 per million in the United States populations \[[@B2]\]. The prevalence of chronic kidney disease (CKD) in Taiwan was 9.8-11.9% \[[@B3]--[@B6]\]. According to the most recent data, the prevalence of CKD in Taiwan increased from 11.9% in 2010 to 15.46% in 2018 \[[@B3], [@B7]\], and the incidence increase from 13.5/1000 person-years in 2003 to 27.21/1000 person-years in 2018 \[[@B7], [@B8]\]. Taiwan had higher prevalence and incidence rate of CKD, which might be due to the aging country and low public perception of the renal disease. A recent meta-analysis showed that ESRD increased the mortality, need for transfusion, rebleeding rate, and length of hospitalization in gastrointestinal (GI) bleeding patients \[[@B9]\]. Several cohort studies also documented that patients with CKD had higher incidences of upper GI bleeding \[[@B10], [@B11]\], peptic ulcer bleeding \[[@B12]--[@B14]\], and recurrent upper GI rebleeding \[[@B15]--[@B17]\] than those without CKD \[[@B18]\]. However, few studies investigate the exact incidence of lower GI bleeding and angiodysplasia bleeding in patients with CKD with or without hemodialysis. Most cohort studies for lower GI bleeding were from the West. Few Eastern countries\' studies were seen.

Lower GI bleeding is an emerging problem for medical doctors. A population-based epidemiological study from Spain demonstrated that the lower GI event rate was increasing from 1996 to 2005 though the upper GI bleeding, and perforation rates were decreasing \[[@B19]\]. The study also showed that lower GI events displayed a higher mortality rate, longer hospitalization, and higher resource utilization than upper GI bleeding \[[@B19]\]. In addition, another study by Patel et al. reported that lower GI bleeding increased mortality rate of in patients with coronary artery disease on triple antithrombotic therapy \[[@B20]\].

Angiodysplasia is an important cause of lower GI bleeding \[[@B21]\]. It is more common in patients with chronic renal failure, and its prevalence is related to the severity of the renal disease \[[@B22]\]. Angiodysplasia bleeding accounts for 19-32% of lower GI bleeding episodes in patients with chronic renal failure compared with 5-6% of bleeding episodes in general population \[[@B23], [@B24]\].

The aims of this study were to investigate the incidence of the lower GI bleeding in dialysis CKD and dialysis-free CKD patients and to identify the factors that are predisposing to the lower GI bleeding.

2. Materials and Methods {#sec2}
========================

An observational cohort study design was conducted. The CKD patients receiving regular hemodialysis (dialysis CKD), CKD patients without hemodialysis (dialysis-free CKD), and controls were selected from 1 million randomly sampled subjects in the National Health Insurance Research Database (NHIRD) of Taiwan. The National Health Insurance (NHI) is the universal health insurance coverage more than 99% residents in Taiwan.

The study protocol was approved by the Institutional Review Board in Kaohsiung Veterans General Hospital, with the number 17-CT8-04 (170627-1).

2.1. Study and Control Group {#sec2.1}
----------------------------

The more than 20-year-old dialysis CKD patients were selected from the NHIRD as the study group between 2000/1/1 and 2012/12/31. And then using the dialysis CKD data in 1 : 2 : 2 to matched by age, gender, comorbidity, and enrollment time with dialysis-free CKD and controls from the same dataset and time periods.

The included subjects were extracted based on the International Classification of Disease, 9th revision, Clinical Modification (ICD-9-CM). Dialysis CKD patients were identified by ICD-9-CM code 585 and with a catastrophic illness card. The index date of the dialysis CKD group was the first appearance of catastrophic illness card. Patients who received the catastrophic card had chronic renal failure and had been receiving regular hemodialysis for at least 3 months. Subjects of dialysis-free CKD were identified by ICD-9-CM 582.0, 582.4, 582.8x, 586, 250.4x, 274.1, 403.x1, 404.x2, and 404.x3, which occurred in the hospitalization claims, or when their names were encountered in the outpatient department 3 times continuously when documents were examined \[[@B12]\]. This definition may correspond to CKD stages 4 and 5. The index date of this group was defined as the first-time diagnosis of CKD.

We excluded patients with renal transplantation, peritoneal dialysis, cirrhosis, GI tract malignancy, inflammatory bowel disease, coagulopathy, vascular insufficiency of the intestine, radiation gastroenteritis or colitis, a history of gastrointestinal bleeding one year before the index date, and a medication history of gastroprotective agents (PPI and H2B) and ulcerogenic agents (NSAID), which had been used for at least 4 weeks in the 8 weeks before the index date.

2.2. End Point {#sec2.2}
--------------

The primary endpoint was lower GI bleeding, which was identified by patients who with any admission diagnosis of ICD-9-CM 562.02, 562.03, 562.12, 562.13, 569.3, 578.1, 578.9, and 569.86, and angiodysplasia bleeding with ICD-9-CM 537.83 and 569.85. The bleeding-related mortality was defined as the last admission with a discharge diagnosis of GI bleeding and discharge due to death or in critical status, or patient\'s withdrawal from the NHI. The incidences of all GI bleeding, lower gastrointestinal (LGI) bleeding, and angiodysplasia bleeding in patients with dialysis CKD, dialysis-free CKD, and the control groups were compared.

2.3. Statistical Analysis {#sec2.3}
-------------------------

The data were represented by frequency (percentage), and continuous variables were expressed as mean ± standard deviation. We compared continuous variables by Student\'s *t* test and/or analysis of variance (ANOVA). Categorical variables were tested by chi-squared test or Fisher\'s exact test. The time survival curve was evaluated by the Kaplan-Meier method to evaluate the cumulative incidence of lower GI bleeding. We compared the competing factors by log-rank test. Finally, we performed Cox proportional hazard regression analysis to evaluate the risk factor of lower GI bleeding. A two-sided *P* value of \<0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Demographic Data {#sec3.1}
---------------------

A total of 574 dialysis CKD patients, 1148 dialysis-free CKD patients, and 1148 controls were selected from the one million NHIRD subjects ([Figure 1](#fig1){ref-type="fig"}). The demographic data of the dialysis CKD, dialysis-free CKD, and control groups are summarized in [Table 1](#tab1){ref-type="table"}. The three study groups had comparable age, gender, and comorbidity. However, the dialysis CKD and dialysis-free CKD groups had higher Charlson scores than that of the control group (1.7 ± 1.5 and 1.5 ± 1.4 vs. 1.4 ± 1.3; *P* \< 0.001). There were also no differences in the frequencies of antithrombotic agent use among the three study groups ([Table 1](#tab1){ref-type="table"}).

3.2. The Rate of GI Bleeding {#sec3.2}
----------------------------

During a mean follow-up of 6.4 years, a total of 175 patients (30.5%) in the dialysis CKD group suffered from GI bleeding episodes and needed hospitalization, with 126 (11.0%) in dialysis-free CKD, and 93 (8.1%) in the control group. Both dialysis CKD and dialysis-free CKD groups had higher incidences of GI bleeding than the control group (*P* \< 0.001 and *P* = 0.019, respectively). In lower GI bleeding, dialysis CKD group also had higher rate compared to dialysis-free CKD and control groups (12.9% vs. 3.6% and 2.8%; both *P* \< 0.001; [Table 2](#tab2){ref-type="table"}). There were no differences in the incidence of lower GI bleeding between the dialysis-free CKD group and control group. Kaplan-Meier survival analysis showed that dialysis CKD group exhibited a higher incidence of lower GI bleeding than dialysis-free CKD and control groups ([Figure 2](#fig2){ref-type="fig"}; both *P* \< 0.0001 by log-rank test). The dialysis CKD group had a higher incidence of angiodysplasia bleeding than dialysis-free CKD and control groups (1.1% vs. 0.1% and 0.1%; both *P* \< 0.003, [Table 2](#tab2){ref-type="table"}) although the case number was small. The dialysis-free CKD group and control group displayed comparable incidence of angiodysplasia bleeding (*P* = 1.00).

3.3. Risk Factors for Lower GI Bleeding {#sec3.3}
---------------------------------------

[Table 3](#tab3){ref-type="table"} lists the independent clinical factors influencing the incidence of lower GI bleeding. Multivariate analysis disclosed that extreme old age (age ≥ 85), male gender, dialysis CKD, and dialysis-free CKD were independent risk factors for lower GI bleeding with adjusted hazard ratios of 61.47 (95% confidence interval (CI): 2.68-1412.10), 3.14 (95% CI: 1.45-6.78), 29.09 (95% CI: 9.66-87.63), and 6.61 (95% CI: 2.27-19.23), respectively.

4. Discussion {#sec4}
=============

In the nationwide population-based cohort study, we investigated the impact of CKD on the incidence of lower GI bleeding and assessed the incidences of angiodysplasia bleeding in patients with CKD and general population. The data clearly demonstrated that dialysis CKD patients had a higher incidence of lower gastrointestinal bleeding than dialysis-free CKD patients and control subjects (12.9% vs. 3.6% and 2.8%; both *P* \< 0.001). Multivariate analysis documented that both CKD under hemodialysis and CKD without hemodialysis were independent factors predicting lower GI bleeding. Additionally, dialysis CKD patients also had a higher incidence of angiodysplasia bleeding than dialysis-free CKD patients and control subjects.

In the baseline characteristics, we found higher Charlson score in the dialysis CKD group. Charlson score included the parameter of severity of renal disease, and this might contribute to the result of the difference. Since Charlson score includes several diseases, and parts of the disease, such as diabetes, hypertension, and celebrovascular accidents, were included in the multivariate analysis, we did not put Charlson comorbidity index (CCI) into multivariate analysis. Further, putting CCI into the analysis would have collinearity or over-control problem.

A retrospective cohort study from Canada showed that the 3-year cumulative incidence of lower GI bleeding in ESRD patients receiving chronic dialysis was 8.9% \[[@B25]\]. In the current study, the annual incidences of lower GI bleeding in the dialysis CKD, dialysis-free CKD, and control groups were 0.80%, 0.32%, and 0.19% person-years, respectively. The dialysis CKD group had a higher cumulative incidence of lower GI bleeding than dialysis-free CKD and control groups (12.9% vs. 3.6% and 2.8%). Multivariate analysis revealed that ESRD was an independent risk factor for lower GI bleeding with an adjusted hazard ratio of 29.1 (95% CI: 9.7-87.6). The promising data presented here are consistent with an independent work in an USA community-based study \[[@B26]\] showing a higher incidence of lower GI bleeding in patients with eGFR (ml/min per 1.73 m^2^) \< 30. The work revealed that the hazard ratios of lower GI bleeding in patients with eGFR≧90, 60-80, 30-59, and \<30 were 1, 1.5, 2.3, and 10.8, respectively.

In the Cox regression analysis, [Table 3](#tab3){ref-type="table"}, we had 15 control variables. According to rule of thumb, Cox model outcome events (at least 10 events per variable (EPV)), we need at least 150 events to get stable estimates of the regression coefficients. In our data, we found 147 lower GI bleeding events, and a little lower than the EPV recommendation. Further result interpretation should be cautious. But in our data, we reported the rare event rates in the real would.

Angiodysplasia is a common and important cause of GI bleeding, especially in patients with CKD. Angiodysplasia bleeding was reported to be associated with chronic renal failure, Von Willebrand\'s disease, aortic stenosis, cirrhosis, and pulmonary disease, but the actual etiology is unknown \[[@B23]\]. Currently, the pathophyiological mechanisms contributing the development of angiodysplasia and consequent bleeding in patients with chronic renal failure are unclear. Several possible causes including uremic platelet dysfunction \[[@B27], [@B28]\] and use of anticoagulants \[[@B29]\] have been proposed to explain the increased risk of bleeding in uremic patients. Further studies are warranted to investigate the pathogenesis of the development of angiodysplasia bleeding in patients with ESRD.

In addition to CKD and hemodialysis, extreme old age, and male gender were independent risk factors predicting lower GI bleeding. Previous studies reported that the prevalence of diverticular disease bleeding and angiodysplasia bleeding increases with age \[[@B30]\], which might explain why old age is associated with higher risks of LGI bleeding. The actual cause of males having a higher risk of lower GI bleeding is unclear. According to previous literature review, males are at higher risk of GI bleeding \[[@B19], [@B31]\]. Further study is needed to confirm the reason for this.

Anticoagulant and antiplatelet agents are reported to be the risk factors for lower GI bleeding \[[@B32], [@B33]\], but still some authors stated that antiplatelet agents were not associated with LGI bleeding \[[@B34]\]. In our study, we found that LGI bleeding had no association with antiplatelet agents and anticoagulants.

There were some limitations to this study. First, this was a retrospective cohort study, and immortal time bias and selection bias might be present in this study. Nonetheless, we have conducted multivariate analysis to identify the independent risk factors predicting lower GI bleeding. Because some patients had CKD and progression to ESRD with or without dialysis for a long time, immortal time bias might exist in this condition. Second, our study was based on the ICD-9-CM code. If the doctors did not input a correct or accurate ICD code for CKD, lower GI bleeding, or angiodysplasia bleeding, we might have missed the case or the clinical events. Third, the stage of CKD could not be well classified because no laboratory data were available in the NHIRD database.

In conclusion, dialysis CKD patients have higher risks of lower GI bleeding and angiodysplasia bleeding than the non-CKD subjects and dialysis-free CKD patients. Hemodialysis, dialysis-free CKD, extreme old age, and male gender were independent risk factors for lower GI bleeding. Further prospective well-designed study is warranted.
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###### 

Demographic characteristics and comorbidities of CKD-HD, CKD dialysis-free, and control groups.

  Variables                                 Dialysis CKD group (*N* = 574)   Dialysis-free CKD group^∗^(*N* = 1148)   Control^∗^(*N* = 1148)   *P* value                  
  ----------------------------------------- -------------------------------- ---------------------------------------- ------------------------ ------------ ----- ------- ------------
  *Age (mean* ± *SD*)                       61 ± 13.0                        62 ± 13.4                                61 ± 13.5                0.61                       
   20-44                                    57                               9.9%                                     93                       8.1%         114   9.9%    0.80
   45-64                                    277                              48.3%                                    559                      48.7%        554   48.3%   
   65-74                                    146                              25.4%                                    308                      26.8%        284   24.7%   
   75-84                                    78                               13.6%                                    163                      14.2%        165   14.4%   
   ≥85                                      16                               2.8%                                     25                       2.2%         31    2.7%    
  *Gender*                                                                                                                                                                
   Male                                     318                              55.4%                                    653                      56.9%        636   55.4%   0.74
   Female                                   256                              44.6%                                    495                      43.1%        512   44.6%   
  *Comorbidities*                                                                                                                                                         
   Alcoholic liver disease and alcoholism   4                                0.7%                                     6                        0.5%         11    1.0%    0.47
   Cirrhosis                                0                                0.0%                                     0                        0.00%        0     0.00%   ---
   Stroke                                   57                               9.9%                                     109                      9.5%         87    7.6%    0.15
   Diabetes mellitus                        363                              63.2%                                    739                      64.3%        714   62.2%   0.56
   Hypertension                             363                              63.2%                                    718                      62.5%        812   70.7%   \<0.001^∗^
   Ischemic heart disease                   130                              22.7%                                    263                      22.9%        276   24.0%   0.75
   Congestive heart failure                 26                               4.5%                                     55                       4.8%         56    4.9%    0.95
   Chronic lung disease                     91                               15.9%                                    185                      16.1%        215   18.7%   0.17
  *Charlson score*                                                                                                                                                        
   0                                        140                              24.4%                                    281                      24.5%        284   24.7%   \<0.001^∗^
   1                                        152                              26.5%                                    404                      35.2%        451   39.3%   
   2                                        119                              20.7%                                    218                      19.0%        232   20.2%   
   ≥3                                       163                              28.4%                                    245                      21.3%        181   15.8%   
  Charlson score (mean ± SD)                1.7 ± 1.5                        1.5 ± 1.4                                1.4 ± 1.3                \<0.001^∗^                 
  *Medication*                                                                                                                                                            
   Aspirin                                  189                              32.9%                                    389                      33.9%        394   34.3%   0.85
   Steroids                                 70                               12.2%                                    143                      12.5%        165   14.4%   0.30
   Warfarin                                 7                                1.2%                                     18                       1.6%         14    1.2%    0.73
   Clopidogrel                              11                               1.9%                                     17                       1.5%         16    1.4%    0.70
   Ticlopidine                              7                                1.2%                                     12                       1.1%         8     0.7%    0.51

^∗^Match (1 : 2 ratio) with age, sex, comorbidities, and enrollment time. CKD: chronic kidney disease; SD: standard deviation.

###### 

The gastrointestinal bleeding and bleeding-related mortality in dialysis CKD and dialysis-free CKD and control groups during a 6.4-year follow-up period.

  Variables                       A: dialysis CKD group (*N* = 574)   B: dialysis-free CKD group (*N* = 1148)   C: control group (*N* = 1148)   *P* value                                         
  ------------------------------- ----------------------------------- ----------------------------------------- ------------------------------- ----------- ---- ------ ------------ ------------ ----------
  All GI bleeding, hospitalized   175                                 30.5%                                     126                             11.0%       93   8.1%   \<0.001^∗^   \<0.001^∗^   0.019^∗^
  Lower GI bleeding               74                                  12.9%                                     41                              3.6%        32   2.8%   \<0.001^∗^   \<0.001^∗^   0.27
  Angiodysplasia bleeding         6                                   1.1%                                      1                               0.1%        1    0.1%   0.003^∗^     0.003^∗^     1.00
  Bleeding related mortality      14                                  2.4%                                      13                              1.13%       0    0      0.0040       \<0.001      0.0003

^∗^ *P* \< 0.05. CKD: chronic kidney disease; GI: gastrointestinal.

###### 

The independent predictors of lower gastrointestinal bleeding by Cox regression analysis.

  Variable                  Univariate analysis   95% CI   Multivariate analysis   95% CI          
  ------------------------- --------------------- -------- ----------------------- -------- ------ ---------
  Control group             1.00                  ---      ---                     1.00     ---    ---
  Dialysis CKD group        5.97                  3.83     9.29                    29.09    9.66   87.63
  Dialysis-free CKD group   1.79                  1.07     3.01                    6.61     2.27   19.23
  Age                                                                                              
   20-44                    1.00                  ---      ---                     1.00     ---    ---
   45-64                    2.91                  0.29     29.64                   3.00     0.26   34.28
   65-74                    3.98                  0.39     41.14                   5.26     0.47   59.08
   75-84                    3.43                  0.34     34.25                   5.04     0.44   57.96
   ≥85                      25.59                 1.57     416.29                  61.47    2.68   1412.10
  Male                      1.89                  1.07     3.33                    3.14     1.45   6.78
  Stroke                    3.13                  1.22     8.03                    2.41     0.67   8.67
  Diabetes mellitus         1.83                  0.89     3.79                    1.84     0.67   5.05
  Hypertension              0.83                  0.45     1.50                    0.84     0.36   1.98
  Ischemic heart disease    0.81                  0.46     1.43                    0.83     0.38   1.80
  Medication                                                                                       
   Aspirin                  2.08                  1.43     3.01                    0.57     0.27   1.20
   Steroids                 2.03                  1.38     2.99                    0.75     0.39   1.43
   Warfarin                 1.50                  0.54     4.18                    1.28     0.33   5.01
   Clopidogrel              2.49                  1.51     4.11                    1.22     0.58   2.57
   Dipyridamole             2.03                  1.33     3.10                    0.88     0.44   1.75
   Ticlopidine              1.23                  0.43     3.54                    0.40     0.11   1.42
  All NSAID                 2.00                  1.39     2.87                    4.00     0.15   107.02
   Selective NSAID          1.54                  0.91     2.59                    0.74     0.35   1.57
   Nonselective NSAID       2.01                  1.40     2.89                    0.11     0.01   2.50

CKD: chronic kidney disease.
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